Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 138

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 138
---
 strategy to address neuroinflammation and promote healthy aging.
The Company is advancing a therapeutic drug pipeline targeting CNS disorders and rare disease, while also entering into the consumer
longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary enhanced
resveratrol formulation that has demonstrated significantly improved bioavailability. The Company’s prescription pipeline is focused
broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease. The Company’s Nugevia line brings clinical-grade
science to the supplement space, supporting mental clarity, skin health and mitochondrial function.

Currently available resveratrol
products are associated with severe gastrointestinal (GI) side effects at the dose levels we believe are needed for therapeutic effect.
Our belief, that a high dose of resveratrol is needed for therapeutic effects, is based on available scientific literature, preclinical
trial results conducted in mice and rats, and previously conducted human trials with resveratrol. We believe that JOTROL™,
based on the results from our Phase I clinical trial conducted at SYNEOS Health, Miami and completed in 2021, has the potential to deliver
a therapeutically effective dose of resveratrol in the blood stream without causing any severe side effects. Based on our own preclinical
studies and scientific publications we believe that resveratrol has the ability to cross the blood-brain barrier. In studies conducted
in Friedreich’s ataxia (FA) and Alzheimer’s disease (AD) patients, JOTROL™ resulted in positive effects on oxidative
stress, inflammation, and mitochondrial function.

The present primary target
for the Company’s pharmaceutical pipeline is the treatment of Parkinson’s Disease (PD). The Company completed preclinical
activities in a validated mouse model of Parkinson’s Disease at the University of Miami in 2021. The model of Parkinson’s
Disease that was used in this clinical trial mimics many aspects of the disease utilizing a unilateral injection of a neurotoxin precursor
that elicits nigral cell loss, striatal dopamine loss and behavior deficits similar to physiological characteristics of human disease.
We believe that results from this clinical trial indicate that Parkinson’s Disease might be the best target for treatment and financial
opportunity among the multiple indications where JOTROL™ might play a role.

The Company is now in process
to start its first Phase II trial in a patient population. This will be a Phase IIa study conducted with the assistance of Zina